Biogen Idec (BIIB)
Create an Alert
203.74
-7.06 -3.35%
NASDAQ
Jun 19, 4:51PM
BATS Real time
Currency in USD
Biogen Idec Revenue Quarterly:
1.415B for March 31, 2013Biogen Idec Historical Revenue Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 1.415B |
| Dec. 31, 2012 | 1.418B |
| Sept. 30, 2012 | 1.386B |
| June 30, 2012 | 1.421B |
| March 31, 2012 | 1.292B |
| Dec. 31, 2011 | 1.327B |
| Sept. 30, 2011 | 1.310B |
| June 30, 2011 | 1.209B |
| March 31, 2011 | 1.203B |
| Dec. 31, 2010 | 1.219B |
| Sept. 30, 2010 | 1.176B |
| June 30, 2010 | 1.213B |
| March 31, 2010 | 1.109B |
| Dec. 31, 2009 | 1.127B |
| Sept. 30, 2009 | 1.121B |
| June 30, 2009 | 1.093B |
| March 31, 2009 | 1.036B |
| Dec. 31, 2008 | 1.069B |
| Sept. 30, 2008 | 1.093B |
| June 30, 2008 | 993.44M |
| March 31, 2008 | Go Pro |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity. Increasing revenues over time are generally a good sign of company's growth.
While a bit obvious, if a lemonade company has sold 30 million in revenue and has 10 million in costs of goods sold, the company's revenue is still 30 million. (Expenses are not accounted in Revenue).
Learn More
BIIB Revenue Quarterly Benchmarks
| Companies | |
|---|---|
| Anika Therapeutics | 15.25M |
| Celgene Corporation | 1.465B |
| Novartis | 14.21B |
BIIB Revenue Quarterly Rankings
| Overall |
91st percentile 1473 of 16782 |
| Sector |
93rd percentile 87 of 1410 in Healthcare |
| Industry |
98th percentile 8 of 454 in Biotechnology |
BIIB Revenue Quarterly Range, Past 5 Years
| Minimum | 993.44M | Jun 2008 |
| Maximum | 1.421B | Jun 2012 |
| Average | 1.211B |
